← All trials
NCT04558021
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 8, 2020
- Primary completion
- Jan 30, 2021
- Completion date
- Feb 14, 2021
- First posted
- Sep 22, 2020
- Last posted
- Oct 12, 2020
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mustafa Nevzat PharmaceuticalsLead sponsor
- O & O Alpan LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.